This a randomised open-label parallel study involving women with polycystic ovary syndrome
(PCOS). The patients will be randomised either to metformin 1500mg or empagliflozin 25mg
daily for three months. The aim of the study is to examine the effect of empagliflozin on
hormonal, metabolic and cardiovascular risk markers and quality of life in women with PCOS.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hull University Teaching Hospitals NHS Trust University of Hull